HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CBD Wellness Market: From Israel To Denver, And Gummies To Series A Rounds

Executive Summary

Aura acts on Israel export law; Israel cannabis firms collaborate; Lucas Brand Equity has $50M for CBD; $27.4M Series A for NorCal; Veteran offers CBD supplements for PTSD; cannabis oral strips from MedPharm;  Mineralife CMO for CBD; and more.

You may also be interested in...

CBD Market: Vitamin Shoppe Enters Field, More Gummies Launched

Nutrition, health and wellness product firm launches its CBD sales with Irwin's Naturals products and also offers SpaRoom oils. Green Gorilla and Folium Biosciences are the latest nutritional product firms to offer CBD-containing supplements in gummy format.

In CBD Market, Endo Supplements At Whole Foods, Axim Plans Oral Care Line

Emerald Health Therapeutics has Whole Foods Markets carrying its products while Diamond CBD pitches its line to CVS Health. Axim Biotechnologies plans to explore production of CBD-based toothpaste as first product under recently patented formulation.

FDA To Consider Regulatory Shift Making Cannabis Ingredients Officially Eligible For Use In Dietary Supplements

FDA's prohibition against using ingredients derived from the cannabis plant in supplements and food isn't lifted by the farm bill President Trump signed on Dec. 20, but the agency recognizes sales of supplement and food products containing cannabidiol and other cannabis derivatives are exploding in the US.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts